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Received July 5, 2010; accepted August 6, 2010AbstractChronic graft-versus-host disease (cGVHD) is one of the most frequent and serious complications of allogeneic hematopoietic stem cell
transplantation (HSCT). Nephrotic syndrome (NS) is an uncommon and underrecognized manifestation of cGVHD. We report a patient who
developed NS 18 months after allogeneic bone marrow transplantation. The onset of NS was accompanied by active manifestations of cGVHD,
and immunosuppressants had not been tapered recently. Renal biopsy revealed membranous nephropathy. The patient failed to improve with
three combined immunosuppressants (prednisolone, cyclosporine, and mycophenolate mofetil), but achieved partial remission after intravenous
immunoglobulin (IVIG) infusion. Twenty-four months after the diagnosis of NS, the patient was still in hematological remission, with normal
serum creatinine level, urinary protein loss of 0.7e1.9 g/day and mild oral mucositis. Our report suggests that NS can be a cGVHD-related
immune disorder in HSCT patients. Monitoring of renal parameters, especially proteinuria, is important in cGVHD patients. Our case indi-
cated that post-transplant NS, occurring without history of tapering or following immunosuppressant withdrawal, presents a more severe activity
of cGVHD and a relatively severe clinical course. IVIG may modify and control the refractory GVHD-related NS, and can be one of the choices
of treatment.
Copyright  2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Chronic graft-versus-host disease (cGVHD) is one of the
most serious and common late complications of allogeneic
hematopoietic stem cell transplantation (HSCT). It occurs in
20e70% of patients surviving >100 days after HSCT, and* Corresponding author. Dr. Ren-Bin Tang, Department of Pediatrics, Taipei
Veterans General Hospital, 201, Sec 2, Shi-Pai Road, Taipei 112, Taiwan,
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doi:10.1016/j.jcma.2011.08.008causes significant morbidity and mortality.1 cGVHD develops
at least 2e3 months after transplantation, presenting as
a systemic autoimmune disorder.2 It frequently affects the
skin, eyes, mouth, serous membranes, liver, gastrointestinal
and respiratory tract.3 Despite increasing knowledge about
cGVHD, nephrotic syndrome (NS) following HSCT remains
an ill-defined entity. It is reported as an uncommon and
underrecognized complication and is usually associated with
cGVHD.4 A close temporal relationship between NS, tapering
or discontinuation of immunosuppressants and simultaneous
cGVHD is observed. The majority of reported cases respond to
immunosuppressive therapy. Here, we present a patient withhinese Medical Association. All rights reserved.
Fig. 1. Skin lesion of chronic graft-versus-host disease. The maculopapular
skin rash over the face is compatible with chronic graft-versus-host disease.
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cyclosporine (CsA), and mycophenolate mofetil (MMF)
therapy. Partial remission was achieved following treatment
with intravenous immunoglobulin (IVIG). To the best of our
knowledge, this is the second case of IVIG used in cGVHD-
related NS.5
2. Case report
An 8-year-old boy was diagnosed with acute lymphoblastic
leukemia (ALL). Surface marker examination of the leukemic
blasts showed MY7 ¼ 4%, MY9 ¼ 2%, B1 ¼ 93%, B4 ¼
97%, HLADR ¼ 95%, Leu4 ¼ 2%, Leu9 ¼ 2%, T11 ¼ 3%,
TDT ¼ 94%, CALA ¼ 97%, CD5 ¼ 1%, CD22 ¼ 97%, and
CD34 ¼ 76%. Karyotypic analysis demonstrated 46,XY,
t(9;22)(q34;q11.2)/46, idem, t(7;9)(q11.2;p23)/46,XY, and
molecular analysis showed bcr-abl fusion gene positive. The
patient received induction, consolidation, and maintenance
chemotherapy, and remission was achieved. Sixteen months
later, ALL relapse was diagnosed. The patient received
another course of chemotherapy, and then bone marrow
aspiration revealed remission status. Two months after the
second remission, he received an allogeneic bone marrow
transplantation from his HLA-identical brother. However,
second relapse was diagnosed 1 month later and he received
another course of chemotherapy and imatinib mesylate treat-
ment. Donor lymphocyte transfusion was given after remission
was achieved again. Four months after allogeneic bone
marrow transplantation, oral mucosal ulceration and mac-
ulopapular skin rash were observed. cGVHD was diagnosed
on the basis of clinical findings, and prednisolone and CsA
were prescribed for treatment. The patient had normal pre- and
post-transplant renal function and was without proteinuria.
Fourteen months after diagnosis of cGVHD the patient
presented with symptoms of NS, including scrotum swelling,
severe bilateral leg, and eyelid edema. In the recent 9 months,
prednisolone and CsA had not been tapered or withdrawn.
He was afebrile, with blood pressure 112/73 mmHg, pulse
of 75/minute, with no respiratory distress. Relapse of ALL
was excluded by confirming a 100% donor chimerism, and
conventional cytogenetics revealed absence of the Phila-
delphia chromosome. The patient had oral mucosal ulceration
and maculopapular skin rash consistent with active manifes-
tations of cGVHD (Fig. 1). Laboratory tests showed that his
white cell count was 6500/cumm, hemoglobin 7.76 mmol/L,
and platelet 318,000/cumm. Serum albumin was 21 g/L, total
protein 42 g/L, blood creatinine 70.72 mmol/L, blood
urea nitrogen 7.50 mmol/L, aspartate transaminase 19 U/L,
alanine transaminase 7 U/L, alkaline phosphatase 82 U/L, and
g-glutamyltransferase 35 U/L. Serum immunoglobulin (Ig)
levels were IgG 3.62 g/L, IgA 0.39 g/L, and IgM 1.64 g/L.
Total cholesterol was 12.82 mmol/L and triglyceride
2.75 mmol/L. Urine test revealed proteinuria 4þ and 24-hour
urinary protein loss was 6.2 g. Search for antinuclear antibody
and anti-double-stranded DNA was negative, and serum
complement levels (C3, C4) were within the normal
range. Tests for hepatitis B virus antigen, hepatitis C,cytomegalovirus IgM, and EpsteineBarr virus IgM were
negative. Renal venous Doppler ultrasonography, abdominal
sonography, and chest X-ray were normal.
A percutaneous renal biopsy was performed, and membra-
nous glomerulonephropathy (MGN) was diagnosed on the
basis of light, immunofluorescence and electron microscopy
(Fig. 2). There was diffuse global thickening and rigidity of
glomerular capillary walls. Mild diffuse segmental expansion
of mesangial matrix was also noted. No interstitial infiltration,
fibrosis, or vascular abnormalities, which may be evidence
for CsA toxicity, were found. Immunofluorescence analysis
showed diffuse granular immune deposition for IgG and mild
deposition for C3 along the capillary loops. Immunofluores-
cence staining was negative for IgA, IgM, C4, and C1q
antibodies. Electron microscopy showed moderate global
subepithelial deposition of electron-dense material with
frequent intramembranous extension. The glomerular base-
ment membrane showed prominent thickening up to 804 nm.
The visceral epithelial foot process showed extensive global
effacement.
The patient was treated with methylprednisolone pulse
therapy for 3 consecutive days, followed by oral prednisolone
(1 mg/kg/day). The dosage of CsA was increased to 4 mg/kg/
day. However, hypoalbuminemia, proteinuria, and edema did
not improve. Owing to resistance to prednisolone and CsA
treatment, MMF was added. One month later, edema had not
resolved, and hypoalbuminemia and heavy proteinuria were
persistent. Very low serum IgG level of 0.97 g/L was noted,
and IVIG with 400 mg/kg was administrated. After the IVIG
infusion, edema resolved and serum albumin returned to
a normal level gradually. Partial remission was achieved 2
weeks later with 24-hour urinary protein loss being 1.48 g.
Evolution of NS was in parallel with the evolution of cGVHD.
Twenty-four months after the diagnosis of NS, the patient was
still in hematological remission, with normal serum creatinine
level, urinary protein loss of 0.7e1.9 g/day, and mild oral
mucositis. The patient is still on immunosuppressive therapy
with prednisolone, CsA, and MMF.
Fig. 2. Renal biopsy findings showing membranous glomerulonephropathy. (A) Hematoxylin and eosin stain: diffuse global thickening and rigidity of glomerular
capillary walls. (B) Electron microscopy: moderate global subepithelial deposition of electron-dense material, prominent thickening of the glomerular basement
membrane, and extensive global effacement of visceral epithelial foot processes.
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Here, we have described a case of NS, which developed 16
months after HSCT and was found to be associated with
cGVHD. Renal biopsy revealed MGN. In previous reported
cases, the majority of patients had evidence of cGVHD, had
recently changed immunosuppressant doses, and responded
well to immunosuppressive medications.4,6 Our case devel-
oped NS without clear-cut relationships with medication
change, but had active manifestations of cGVHD at MGN
diagnosis and responded poorly to three combined immuno-
suppressant treatments. Our case indicates that post-transplant
NS, occurring without history of tapering or following
immunosuppressant withdrawal, shows a more severe activity
of cGVHD. It presents a relatively severe clinical course and
poor clinical response to treatment. IVIG, with immunomod-
ulatory efficacy, was effective in this refractory GVHD-related
NS. To the best of our knowledge, this is the second case to
show that IVIG is effective in reducing proteinuria in patients
with cGVHD-related NS.5
Renal involvement is an uncommon and underrecognized
manifestation during the course of cGVHD. MGN has been
found in two-thirds of patients with GVHD-related NS.6
Other renal diseases, such as minimal change disease, focal
segmental glomerulonephritis, diffuse proliferative glomerulo-
nephritis, IgA nephropathy, membranoproliferative glomeru-
lonephritis, and antineutrophil cytoplasmic antibody-associated
glomerulonephritis, have also been described.7 Many features
seen in cGVHD are similar to those of autoimmune diseases,
such as systemic lupus erythematosus, systemic sclerosis,
Sjo¨gren’s syndrome, primary biliary cirrhosis, myasthenia
gravis, and polymyositis.8,9 Because circulating or in situ
immune complexes are responsible for the features of MGN,
post-HSCT MGN may represent another consequence of this
graft-versus-host conflict. In experimental studies, lupus
nephritis was induced by murine GVHD models.7,8 These
findings support that an immune complex-mediated mecha-
nism during the course of GVHD may have a role in the
pathogenesis of MGN.The most used treatment options include prednisolone and
CsA in post-HSCT MGN patients. Other agents have been
used in the past for GVHD-related glomerular disease, such
as cyclophosphamide, tacrolimus, MMF and rituximab, and
clorambucil.4,6 However, the appropriate treatment, dose, and
duration of immunosuppressive medication is still unknown.
Response of post-HSCT MGN to treatment with prednisolone
and immunosuppressant is variable: 27% showed complete
and 62% showed partial remission.9 Furthermore, chronic
immunosuppressant therapy has multiple toxicities. Prolonged
exposure to immunosuppressive medication facilitates the
development of new cancers or relapse of disease.1 Stevenson
et al10 reported two cases of NS after HSCT: relapsed solid
organ and bone marrow leukemia were diagnosed following
reintroduction of CsA. Therefore, the prescription of immu-
nosuppressive medication should be very cautious, and new
approaches to treating cGVHD is an emerging approach.1
IVIG is a complex product that has been used as an adjunct
to antibacterial and antiviral therapy. IVIG, with the effects of
anti-idiotypic regulation and inhibition of cytokines, has also
been hypothesized to modulate or reduce the severity of acute
GVHD.11 In clinical studies, the role of IVIG therapy in
prevention and treatment of GVHD is vague.12 Several large
controlled trials showed that administration of IVIG prevented
infection in patients undergoing HSCT and reduced the inci-
dence of acute GVHD,13 and other studies failed to show
a statistically significant benefit.12 Sullivan et al demonstrated
that passive immunotherapy with IVIG had immunomodula-
tory and antimicrobial efficacy in HSCT patients.14 Further-
more, the use of IVIG is standard in HSCT patients with severe
hypogammaglobulinemia in many centers.2,13,15 In our case,
IVIG infusion accompanied partial remission of proteinuria
and regression of edema in immunosuppressant-refractory NS.
The prompt clinical response suggested the role of immuno-
modulation of IVIG in post-HSCT NS. Combined or coinci-
dent response with other immunosuppressive therapy is another
consideration. In a previously reported case, immunosuppres-
sant, IVIG, and plasma exchange were prescribed to achieve
partial remission.5 Unlike previous reports, recent studies show
422 H.-H. Wang et al. / Journal of the Chinese Medical Association 74 (2011) 419e422that post-HSCT MGN treatment is burdened by high morbidity
and mortality rates.5,6 According to our report, IVIG may be
one of the choices to modify GVHD when patients do not
respond to multiple immunosuppressive interventions.
In conclusion, our report supports that NS can be
a cGVHD-related immune disorder in HSCT patients. Moni-
toring of renal parameters, especially proteinuria, is important
in cGVHD patients. Although the pathogenesis of GVHD-
related glomerular disease after HSCT remains elusive, our
case underlines the possible importance of IVIG in modifying
and controlling GVHD-related NS. Further study of larger
cohorts is mandatory to delineate the therapeutic benefits of
IVIG in NS associated with cGVHD.References
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